The U.S. Food and Drug Administration granted accelerated approval to Gilead Company Kite’s Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

The gout medication colchicine will be tested in a large UK study looking into potential early-stage Covid-19 treatments and enrollment criteria was widened for the latest arm of the trial, University of Oxford researchers said on March 3.

The U.S. government on Feb. 27 authorized Johnson & Johnson’s single-dose Covid-19 vaccine, enabling millions more Americans to be vaccinated in the coming weeks and setting the vaccine up for additional approvals around the world.

The U.S. Food and Drug Administration accepted for Priority Review Pfizer Inc.’s Biologics License Application for TicoVac, the company’s tick-borne encephalitis vaccine for active immunization to prevent TBE in individuals 1 year of age and older.

The U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.

The U.S. Food and Drug Administration approved Janssen Pharmaceuticals’ Darzalex Faspro for adults with newly diagnosed light chain amyloidosis.

Alexion Pharmaceuticals Inc. paused enrollment in a late-stage study testing the company’s rare blood-disorder drug in adults with severe Covid-19 requiring mechanical ventilation.

Supernus Pharmaceuticals Inc.’s experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

Ridgeback Biotherapeutics LP’s Ebanga is the first FDA-approved, single-injection Ebola treatment which is available in a lyophilized form.